These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. The influence of RS-61443 on antibody-mediated rejection. Knechtle SJ; Wang J; Burlingham WJ; Beeskau M; Subramanian R; Sollinger HW Transplantation; 1992 Mar; 53(3):699-701. PubMed ID: 1549873 [No Abstract] [Full Text] [Related]
24. FK 506 and deoxyspergualin: additive immunosuppressive effect on rat cardiac allograft rejection in vivo and mitogen-stimulated human lymphocyte responses in vitro. Jiang H; Takahara S; Li D; Namiki M; Ishibashi M; Okuyama A; Sonoda T Transplant Proc; 1994 Aug; 26(4):2313-6. PubMed ID: 7520631 [No Abstract] [Full Text] [Related]
25. Brequinar and brequinar analogues in rat allo- and xenotransplantation. Schuurman HJ; Tanner M; Pally C; Jaffee BD Transplant Proc; 1998 Aug; 30(5):2240-3. PubMed ID: 9723456 [No Abstract] [Full Text] [Related]
26. Evaluation of the use of brequinar sodium and cyclosporine combination therapy for preventing rat cardiac allograft rejection. Cosenza CA; Cramer DV; Eiras-Hreha G; Cajulis E; Wang HK; Makowka L Transplant Proc; 1993 Jun; 25(3 Suppl 2):57-8. PubMed ID: 8516945 [No Abstract] [Full Text] [Related]
27. Synergistic activity of the triple combination: cyclosporine, rapamycin, and brequinar. Stepkowski SM; Kahan BD Transplant Proc; 1993 Jun; 25(3 Suppl 2):29-31. PubMed ID: 8516939 [No Abstract] [Full Text] [Related]
29. Complete control of humoral and cell-mediated xenoreactions with the combination of leflunomide and cyclosporine. Chong AS; Shen J; Xiao F; Blinder L; Foster P; Sankary H; Williams JW Transplant Proc; 1996 Apr; 28(2):684. PubMed ID: 8623344 [No Abstract] [Full Text] [Related]
30. Enhancement of allograft survival by combination RS-61443 and DUP-785 therapy. Kawamura T; Hullett DA; Suzuki Y; Bechstein WO; Allison AM; Sollinger HW Transplantation; 1993 Apr; 55(4):691-4; discussion 694-5. PubMed ID: 8475537 [TBL] [Abstract][Full Text] [Related]
31. Effect of a new immunosuppressive agent, KF20444, in rat cardiac transplantation. Nomura M; Yamashita K; Takehara M; Omura T; Nakajima H; Kishida A; Furukawa H; Todo S Transplant Proc; 1999; 31(1-2):1206-7. PubMed ID: 10083539 [No Abstract] [Full Text] [Related]
32. Endothelial cell antigens associated with accelerated cardiac graft rejection in the rat. Yasunaga C; Cramer DV; Tuso PJ; Fujioka H; Barnett M; Yanaga K; Sugimachi K; Makowka L Transplant Proc; 1995 Feb; 27(1):495-6. PubMed ID: 7879075 [No Abstract] [Full Text] [Related]
33. Inhibition of the pyrimidine biosynthetic pathway with S-8660, an analogue of brequinar sodium, prolongs cardiac allograft survival in rats. Cramer DV; Chapman FA; Jaffee B; Jones EA; Makowka L J Heart Lung Transplant; 1993; 12(1 Pt 1):140-6. PubMed ID: 8443191 [TBL] [Abstract][Full Text] [Related]
34. Effect of FK 506 and antiproliferative agents for heart and liver xenotransplantation from hamster to rat. Murase N; Demetris AJ; Tanabe M; Miyazawa H; Valdivia LA; Nakamura K; Starzl TE Transplant Proc; 1993 Feb; 25(1 Pt 1):425-6. PubMed ID: 7679817 [No Abstract] [Full Text] [Related]
35. Inhibition of natural antibody synthesis by cyclophosphamide or 15-deoxyspergualin fails to prevent xenograft rejection in the guinea pig-to-rat model. Leventhal JR; Platt JL; Flores HC; Gruber SA; Matas AJ; Bolman RM Transplant Proc; 1992 Apr; 24(2):551. PubMed ID: 1566426 [No Abstract] [Full Text] [Related]
36. Paclitaxel saves rat heart allografts from rejection by inhibition of the primed anti-donor humoral and cellular immune response: implications for transplant patients with cancer. Tange S; Scherer MN; Graeb C; Andrassy J; Justl M; Frank E; Jauch KW; Geissler EK Transpl Int; 2003 Jul; 16(7):471-5. PubMed ID: 12677363 [TBL] [Abstract][Full Text] [Related]
37. KRP-203, a novel synthetic immunosuppressant, prolongs graft survival and attenuates chronic rejection in rat skin and heart allografts. Shimizu H; Takahashi M; Kaneko T; Murakami T; Hakamata Y; Kudou S; Kishi T; Fukuchi K; Iwanami S; Kuriyama K; Yasue T; Enosawa S; Matsumoto K; Takeyoshi I; Morishita Y; Kobayashi E Circulation; 2005 Jan; 111(2):222-9. PubMed ID: 15642767 [TBL] [Abstract][Full Text] [Related]
38. The significance of timing of additional short-term immunosuppression in the donor-specific transfusion/cyclosporine-treated rat. Levy AE; Alexander JW Transplantation; 1996 Jul; 62(2):262-6. PubMed ID: 8755826 [TBL] [Abstract][Full Text] [Related]
39. The new cyclosporine derivative, SDZ IMM 125: in vitro and in vivo pharmacologic effects. Hiestand PC; Gräber M; Hurtenbach U; Herrmann P; Cammisuli S; Richardson BP; Eberle MK; Borel JF Transplant Proc; 1992 Aug; 24(4 Suppl 2):31-8. PubMed ID: 1386701 [No Abstract] [Full Text] [Related]
40. Anti-B cell agents: suppression of natural antibodies and prolongation of survival in discordant xenografts. Blakely ML; Van der Werf WJ; Dalmasso AP; Bach FH Transplant Proc; 1994 Jun; 26(3):1374-5. PubMed ID: 8029946 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]